Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ Form 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH ...

The Transplant Solutions Company •F E B R U A R Y 2 6 , 2 0 2 5 Click to edit Master text styles Click to edit Master title style Patrick G, Kidney Transplant Recipient Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, i ...

CareDx, Inc (NASDAQ:CDNA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Bill Bonello - Craig-Hallum Andrew Cooper - Raymond James Mason Carrico - Stephens Eduardo Martinez - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good afternoon, everyone. Welcome to the CareDx, Inc. Fourth Qua ...

Core Insights - CareDx reported $86.58 million in revenue for Q4 2024, a 32% year-over-year increase, with an EPS of $0.18 compared to -$0.17 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $85.5 million by 1.26%, and the EPS surpassed the consensus estimate of $0.07 by 157.14% [1] Revenue Breakdown - Revenue from Patient and Digital Solutions was $11.39 million, exceeding the average estimate of $10.99 million by analysts, representing an 18.4% year-over-year increase [4] - Revenue from Testing Services reached $63.82 million, compared to the average estimate of $62.20 million, marking a 36.7% year-over-year increase [4] - Revenue from Products was $11.37 million, surpassing the average estimate of $10.83 million, reflecting a 23% year-over-year increase [4] Stock Performance - CareDx shares have returned -8.5% over the past month, while the Zacks S&P 500 composite has changed by -2.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Registrant's telephone number, including area code N/A (Former Name, or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy ...

Core Insights - CareDx (CDNA) shares increased by 11.2% to $24.91, following a significant trading volume, contrasting with a 5.2% decline over the past month [1] - The upcoming fourth-quarter 2024 financial results are anticipated to show approximately 30% year-over-year revenue growth, with testing services volume increasing by 14% [2] - The consensus EPS estimate for the quarter is $0.07, reflecting a year-over-year increase of 141.2%, with expected revenues of $85.5 million, up 30.4% from the previous year [3] Earnings and Revenue Expectations - Adjusted EBITDA is projected to be between $25 million and $26 million for the fourth quarter [2] - The consensus EPS estimate has been revised 13.2% higher in the last 30 days, indicating a positive trend that typically leads to price appreciation [4] Industry Context - CareDx is part of the Zacks Medical Services industry, which includes other companies like LifeMD, Inc. (LFMD), that saw a 5.5% increase in its last trading session [4] - LifeMD's EPS estimate remains unchanged at -$0.06, representing a 50% year-over-year change [5]

CareDx (CDNA) closed the last trading session at $23.10, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $32.86 indicates a 42.3% upside potential.The average comprises seven short-term price targets ranging from a low of $24 to a high of $40, with a standard deviation of $6.39. While the lowest estimate indicates an increase of 3.9% from the current price level, the m ...

Company Overview - CareDx (CDNA) is a notable stock within the Medical group, which consists of 1010 companies and currently ranks 3 in the Zacks Sector Rank [2] - CareDx has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook with a 36.9% increase in the consensus estimate for full-year earnings over the past quarter [3] Performance Comparison - Year-to-date, CareDx has returned approximately 6.7%, significantly outperforming the Medical sector's average return of -0.6% [4] - In comparison, DaVita HealthCare (DVA) has also outperformed the sector with a year-to-date return of 15.8% [4] Industry Context - CareDx operates within the Medical Services industry, which includes 59 companies and currently ranks 151 in the Zacks Industry Rank; this industry has seen an average loss of 6.7% this year, highlighting CareDx's superior performance [5] - DaVita HealthCare belongs to the Medical - Outpatient and Home Healthcare industry, which consists of 18 stocks and is ranked 69, with a year-to-date increase of 16.9% [6]

Core Insights - CareDx (CDNA) shares increased by 6.1% to close at $25.07, attributed to higher trading volume compared to typical sessions, with a 3.4% gain over the past four weeks [1] Financial Performance - CareDx is expected to report preliminary fourth-quarter 2024 revenues between $85 million and $86 million, reflecting a 30% year-over-year increase, surpassing the Zacks Consensus Estimate of 25.2% growth [2] - Testing service revenue is projected to rise nearly 35% year-over-year, driven by a 14% increase in volumes [2] - The company anticipates quarterly earnings of $0.07 per share, representing a year-over-year increase of 141.2%, with revenues expected to reach $82.12 million, up 25.2% from the previous year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for CareDx has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - CareDx currently holds a Zacks Rank of 3 (Hold), while another company in the medical services industry, Avantor, Inc. (AVTR), has a Zacks Rank of 4 (Sell) [4]

Group 1 - The article discusses the process of identifying potential investment opportunities for the "Bioreactor" growth portfolio within the Compounding Healthcare Investing Group [1] - The focus is on innovative companies that are developing breakthrough therapies and pharmaceuticals, particularly those with catalysts for potential acquisitions [3] - The investing group offers several model healthcare portfolios, a weekly newsletter, a daily watchlist, and a platform for dialogue and questions among members [4] Group 2 - The author has a beneficial long position in the shares of TMO and BIO, indicating a personal investment interest in these companies [1] - The article encourages readers to explore the subscription marketplace service, Compounding Healthcare, for more insights into investment methods and opportunities [2]